ArticleInternational journal of molecular sciences2025

Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab.

Lothar Marischen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.